Quality of life and treatment burden of children receiving daily growth hormone treatment in Greece
A good HRQoL and a mild treatment burden were reported by Greek patients receiving daily rhGH and their caregivers; however, variability was observed within children's and caregivers' groups. Considering the decreased compliance during adolescence, emphasis should be given to consultations with patients and caregivers to identify issues and address them accordingly. Finally, there is a need to consider alternative treatment regimens which could improve adherence.
Authors
- Dimitrios Tsilakis
- Athanasios Christoforidis (ORCID: https://orcid.org/0000-0003-4964-5726)
- Assimina Galli‐Τsinopoulou (ORCID: https://orcid.org/0000-0002-8503-3893)
- Ioannis Skiadas (ORCID: https://orcid.org/0000-0002-4964-0266)
- Evangelia Baxevanidi
- Elpis-Athina Vlachopapadopoulou
- Dionisios Chrysis (ORCID: https://orcid.org/0000-0002-7779-9207)
- Oresteia Zisimopoulou
- Christina Kanaka‐Gantenbein (ORCID: https://orcid.org/0000-0002-6963-5464)
- Apostolia Poimenidou
- Fotini-Eleni Karachaliou
Institutions
- University of Patras (GR)
- National and Kapodistrian University of Athens (GR)
- Aristotle University of Thessaloniki (GR)
- AHEPA University Hospital (GR)
- General University Hospital of Patras (GR)
- Ippokrateio General Hospital of Thessaloniki (GR)
- Children's Hospital Agia Sophia (GR)
- Panagiotis & Aglaia Kyriakou Children's Hospital (GR)
Publication Details
- Journal
- Endocrine
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1007/s12020-025-04269-w
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Novo Nordisk
- National and Kapodistrian University of Athens
- Aristotle University of Thessaloniki